Skip to main content

Table 1 Clinical trials where MRD guides treatment decisions. Results are based on a search in the ‘’ website that included the terms “multiple myeloma” and “MRD”, and individual identification of clinical trials where treatment algorithms were triggered by patients’ MRD status. Selected studies (identified with an asterisk) were added based on knowledge of their existence, despite being absent in search results. It should be noted that many more studies assess MRD and in most clinical trials, MRD response rates are a primary or secondary endpoint (see Fig. 1). However, because no apparent treatment decision is being made based on patients’ MRD status, those studies were not included in the table below. There are many clinical trials that, to the best of our knowledge, will have MRD-guided treatment decisions but were not added because their design is still being finalized or have not been initiated at the time of this publication

From: Measurable residual disease in multiple myeloma: ready for clinical practice?

NCTStudy official titleCountryTechnique
NCT02406144Maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and ixazomib after autologous hematopoietic stem cell transplantation in patients With newly diagnosed symptomatic multiple myeloma-duration of maintenance guided by MRD status (GEM2014MAIN)SpainNGF
RADAR*Risk adapted therapy directed according to response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma suitable for stem cell transplantationUKN/A
NCT03490344Short course daratumumab in minimal residual disease (MRD) positive myeloma patients after induction therapy with/without consolidative high-dose chemotherapy/autologous stem cell supportUSAFC
NCT03224507Monoclonal antibody-based sequential therapy for deep remission in multiple myeloma (MASTER)USANGS
NCT03742297*Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide, and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma patients aged between 65 and 80 yearsSpainNGF
NCT03697655Pre-emptive daratumumab therapy of minimal residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR)PolandN/A
NCT03710603A phase 3 study comparing daratumumab, VELCADE (Bortezomib), lenalidomide, and dexamethasone (D-VRd) vs VELCADE, lenalidomide, and dexamethasone (VRd) in subjects with previously untreated multiple myeloma who are eligible for high-dose therapy (PERSEUS)EMNN/A
NCT03992170A pilot study on the efficacy of daratumumab in multiple myeloma (MM) patients in >VGPR/MRD-positive by next-generation flow (DART4MM)ItalyFC
NCT02969837Open-label, single-arm, phase 2 study of initial treatment with elotuzumab, carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone (E-KRd) in newly diagnosed, multiple myeloma requiring systemic chemotherapyUSANGS and MFC
NCT04071457S1803, phase III study of daratumumab/rHuPH20 (NSC-810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (DRAMMATIC study)USANGS
NCT04096066Carfilzomib-lenalidomide-dexamethasone (KRd) versus lenalidomide-dexamethasone (Rd) in newly diagnosed myeloma patients not eligible for autologous stem cell transplantation: a randomized phase III trialItalyN/A
NCT03376477A randomized, double-blind, placebo-controlled phase II trial of an allogeneic myeloma GM-CSF vaccine with lenalidomide in multiple myeloma patients in complete or near completeUSANGS
NCT04108624A multimodality approach to minimal residual disease detection to guide post-transplant maintenance therapy in multiple myeloma (MRD2STOP)USANGS
NCT04221178A single-arm, prospective atudy of maintenance therapy cessation for patients with multiple myeloma in sustained MRD-negative remissionsUSANGF
NCT04140162Phase 2 study with minimal residual disease (MRD) driven adaptive strategy in treatment for newly diagnosed multiple myeloma (MM) with upfront daratumumab-based therapyUSAN/A
  1. NGS next-generation sequencing, FC flow cytometry, NGF next-generation flow cytometry, N/A not available, EMN European Myeloma Network